

CV Summary

Eva Giné Soca, MD

FILIATION

Eva GINÉ SOCA, MD

Born in Lleida (Spain) in October 5th, 1973

Work address: Department of Hematology, Hospital Clínic, Villarroel 170 - 08036 Barcelona – Spain

CURRENT POSITION

Consultant, Department of Hematology, Hospital Clínic, Barcelona, Spain

EDUCATION AND TRAINING

- Medical School, University of Lleida: Degree in Medicine and Surgery (June 1997)
- Hospital Clínic / Spanish Ministry of Health: Specialty in Hematology and Hemotherapy (May 2002)
- Medical School, University of Barcelona: Doctoral Thesis (June 2010)
- Postgraduate Statistical Studies in Health Sciences (27 ECTS). University Autònoma of Barcelona (June 2012)
- Postdoctoral Fellowship, Centre for Lymphoid Cancers, BC Cancer Agency, Vancouver (March 2015-February 2016)

RESEARCH AND PROFESSIONAL EXPERIENCE

Professional Experience:

- Fellow Physician (Departments of Medicine and Hematology, Hospital Clínic) 1998-2002
- Research Fellow (Department of Hematology, Hospital Clínic) 2002-2005
- Emergency Physician (Department of Hematology, Hospital Clínic) 2005-2010
- Interim Physician ((Department of Hematology, Hospital Clínic) 2007-2010
- Staff Physician (Department of Hematology, Hospital Clínic) 2010-present
- Tutor of Hematology fellows (Department of Hematology, Hospital Clínic) 2011-present
- Investigator in clinical trials (Department of Hematology, Hospital Clínic) 2002-present
- Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), investigator in the group for the study of lymphoproliferative disorders 2010-present
- Postdoctoral fellowship (Centre for Lymphoid Cancers, BC Cancer Agency): March 2015-February 2016

Other experience and professional memberships:

- Catalan Group for the Study of Lymphomas (GELCAB) (2002-present)
- National Spanish group GELTAMO (2010-present)
- European Mantle Cell Lymphoma Study Group (2012-present)
- International Extranodal Lymphoma Study Group (2013-present)
- ESMO Faculty (2021-present)

Clinical Trials experience:

- Experience in conducting different clinical trials in lymphoproliferative disorders since 2002.
- At present I am especially involved in clinical trials of mantle cell lymphoma (MCL). I lead within the GELTAMO group the IMCL-2015 study (NCT 02682641), a phase II trial that explores the combination of Ibrutinib and Rituximab in indolent clinical forms of MCL. This study has a translational study associated to allow the biological characterization of these forms, including *Whole Exome Sequencing (WES)*.

In addition, I am in charge of the coordination in Spain, on behalf the GELTAMO group, of the European TRIANGLE trial (EU MCL network).

Research lines:

- I have participated as co-Investigator on several grants focused on lymphoproliferative studies in close collaboration with Dr López-Guillermo and Dr. E. Campo. I have been involved in different cooperative groups, including the Spanish group of lymphomas (GELTAMO), the International Extranodal Lymphoma Study group and the European MCL Network.
- Studies of Cell-free DNA in aggressive B-cell lymphomas
- Mantle cell lymphoma, focusing in the biological description of indolent clinical forms and the characterization of the central nervous system infiltration in these patients
- The topic of histological transformation in follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)
- CLL, with the goal of identifying mechanisms of progression in this disease along with the study of the different apoptotic mechanisms induced by drugs in CLL

Selected publications (last 5 years):

1. Giné E, de la Cruz F, Jiménez Ubieta A, López Jimenez J, Martín García-Sancho A, Terol MJ, González Barca E, Casanova M, de la Fuente A, Marín-Niebla A, Muntañola A, González-López TJ, Aymerich M, Setoain X, Cortés-Romera M, Rotger A, Rodríguez S, Medina Herrera A, García Sanz R, Nadeu F, Beà S, Campo E, López-Guillermo A. Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial. *J Clin Oncol*. 2022;40(11):1196-1205
2. Rivas-Delgado A, Nadeu F, Enjuanes A, Sebastián, Casanueva-Eliceiry S, Pablo Mozas P, Magnano L, Castrejón de Anta N, Rovira J, Dlouhy I, Martín S, Osuna M, Rodríguez S, Simó M, Pinyol M, Baumann T, Beà S, Balagué O, Delgado J, Villamor V, Setoain X, Campo E, Giné E and López-Guillermo A. Mutational Landscape and Tumor Burden Assessed by Cell-Free DNA in Diffuse Large B-Cell Lymphoma: a Population-based Study. *Clin Cancer Res*, Oct 2020 DOI:10.1158/1078-0432
3. Ortíz-Maldonado V, Rives S, Castellà M, Alonso-Saladríguez A, Benítez-Ribas D, Caballero-Baños M, Baumann T, Cid J, García-Rey E, Llanos C, Torredadell M, Villamor N, Giné E, Díaz-Beyá M, Guardia L, Montoro M, Català A, Faura A, González EA, Español-Rego M, Klein-González N, Alsina L, Castro P, Jordan I, Fernández S, Ramos F, Suñé G, Perpiñá U, Canals JM, Lozano M, Trias E, Scalise A, Varea S, Sáez-Peñataro J, Torres F, Calvo G, Esteve J, Urbano-Ispizua Á, Juan M, Delgado CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies. *J.Mol Ther*. 2020 Sep 20:S1525-0016(20)30484-6.
4. Nadeu F, Martín-García D, Clot G, Díaz-Navarro A, Duran-Ferrer M, Navarro A, Vilarrasa-Blasi R, Kulis M, Royo R, Gutiérrez-Abril J, Valdés-Mas R, López C, Chapaprieta V, Puiggros M, Castellano G, Costa D, Aymerich M, Jares P, Espinet B, Muntañola A, Ribera-Cortada I, Siebert R, Colomer D, Torrents D, Gine E, López-Guillermo A, Küppers R, Martín-Subero JI, Puente XS, Beà S, Campo E Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. *Blood*. 2020 Sep 17;136(12):1419-1432.
5. Cryptic insertions of the immunoglobulin light chain enhancer region near CCND1 in t(11;14)-negative mantle cell lymphoma. Fuster C, Martín-García D, Balagué O, Navarro A, Nadeu F, Costa D, Prieto M, Salaverria I, Espinet B, Rivas-Delgado A, Terol MJ, Giné E, Forcada P, Ashton-Key M, Puente XS, Swerdlow SH, Beà S, Campo E. *Haematologica*. 2020 Aug;105(8):e408-e411.
6. Vidal-Crespo A, Matas-Céspedes A, Rodríguez V, Rossi C, Valero JG, Serrat N, Sanjuan-Pla A, Menéndez P, Roué G, López-Guillermo A, Giné E, Campo E, Colomer D, Bezombes C, van Bueren JL, Chiu C, Doshi P, Pérez-Galán P.

- Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. *Haematologica*. 2020 Apr;105(4):1032-1041.
7. Mozas P, Nadeu F, Rivas-Delgado A, Rivero A, Garrote M, Balagué O, González-Farré B, Veloza L, Baumann T, Giné E, Delgado J, Villamor N, Campo E, Magnano L, López-Guillermo A. Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience. *Blood Cancer J*. 2020 Mar 5;10(3):31.
 8. Petrakis G, Veloza L, Clot G, Giné E, Gonzalez-Farre B, Navarro A, Bea S, Martínez A, Lopez-Guillermo A, Amador V, Ribera-Cortada I, Campo. Increased tumour angiogenesis in SOX11-positive mantle cell lymphoma. *E.Histopathology*. 2019 Nov;75(5):704-714
 9. Rivas-Delgado A, Magnano L, Moreno-Velázquez M, García O, Nadeu F, Mozas P, Dlouhy I, Baumann T, Rovira J, González-Farre B, Martínez A, Balague O, Delgado J, Villamor N, Giné E, Campo E, Sancho-Cia JM, López-Guillermo A. Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. *Br J Haematol*. 2019 Mar;184(5):753-759.
 10. Giménez N, Martínez-Trillos A, Montraveta A, Lopez-Guerra M, Rosich L, Nadeu F, Valero JG, Aymerich M, Magnano L, Rozman M, Matutes E, Delgado J, Baumann T, Giné E, González M, Alcoceba M, Terol MJ, Navarro B, Colado E, Payer AR, Puente XS, López-Otín C, Lopez-Guillermo A, Campo E, Colomer D, Villamor N. Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia. *Haematologica*. 2019 Mar;104(3):576-586.
 11. Dang NH, Ogura M, Castaigne S, Fayad LE, Jerkeman M, Radford J, Pezzutto A, Bondarenko I, Stewart DA, Shnaidman M, Sullivan S, Vandendries E, Tobinai K, Ramchandren R, Hamlin PA, Giné E, Ando K. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. *Br J Haematol*. 2018 Aug;182(4):583-586.
 12. Mozas P, Rivas-Delgado A, Baumann T, Villamor N, Ortiz-Maldonado V, Aymerich M, Costa D, Navarro A, Giné E, López-Guillermo A, Montserrat E, Delgado. Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia. *J.Blood Cancer J*. 2018 Jan 16;8(1):10.
 13. Martínez-Trillos A, Pinyol M, Delgado J, Aymerich M, Rozman M, Baumann T, González-Díaz M, Hernández JM, Alcoceba M, Muntañola A, Terol MJ, Navarro B, Giné E, Jares P, Beà S, Navarro A, Colomer D, Nadeu F, Colado E, Payer AR, García-Cerecedo T, Puente XS, López-Otín C, Campo E, López-Guillermo A, Villamor N. The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia. *Leuk Lymphoma*. 2018 Oct;59(10):2318-2326.
 14. Matas-Céspedes A, Vidal-Crespo A, Rodriguez V, Villamor N, Delgado J, Giné E, Roca-Ho H, Menéndez P, Campo E, López-Guillermo A, Colomer D, Roué G, Wiestner A, Parren PW, Doshi P, van Bueren JL, Pérez-Galán P. The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia. *Clin Cancer Res*. 2017 Mar 15;23(6):1493-1505
 15. Kridel R, Chan FC, Mottok A, Boyle M, Farinha P, Tan K, Meissner B, Bashashati A, McPherson A, Roth A, Shumansky K, Yap D, Ben-Neriah S, Rosner J, Smith MA, Nielsen C, Giné E, Telenius A, Ennishi D, Mungall A, Moore R, Morin RD, Johnson NA, Sehn LH, Tousseyn T, Dogan A, Connors JM, Scott DW, Steidl C, Marra MA, Gascoyne RD, Shah SP. Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. *PLoS Med*. 2016 Dec 13;13(12):e1002197. doi: 10.1371/journal.pmed.1002197. eCollection 2016 Dec.
 16. Giné E, Sehn LH. Diffuse Large B-Cell Lymphoma: Should Limited-Stage Patients Be Treated Differently? *Hematol Oncol Clin North Am*. 2016 Dec;30(6):1179-1194.
 17. Queirós AC, Beekman R, Vilarrasa-Blasi R, Duran-Ferrer M, Clot G, Merkel A, Raineri E, Russiñol N, Castellano G, Beà S, Navarro A, Kulis M, Verdaguer-Dot N, Jares P, Enjuanes A, Calasanz MJ, Bergmann A, Vater I, Salaverría I, van de Werken HJG, Wilson WH, Datta A, Flicek P, Royo R, Martens J, Giné E, Lopez-Guillermo A, Stunnenberg HG, Klapper W, Pott C, Heath S, Gut IG, Siebert R, Campo E, Martín-Subero. Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage. *Jl.Cancer Cell*. 2016 Nov 14;30(5):806-821.